Securities code: 603168 securities abbreviation: Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) Announcement No.: pro 2022-008 Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168)
Stock trading abnormal fluctuation announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) (hereinafter referred to as “the company”) has deviated from the closing price by more than 20% in two consecutive trading days (January 10 and January 11, 2022). According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it is an abnormal fluctuation of stock trading.
After the company’s self-examination and verification with the actual controller, controlling shareholder and persons acting in concert of the company, it is confirmed that there are no major matters that should be disclosed but not disclosed as of the disclosure date of this announcement.
1、 Details of abnormal fluctuations in stock trading
Within two consecutive trading days (January 10 and January 11, 2022), the cumulative deviation of the closing price increase of the company’s stock trading exceeds 20%, which belongs to the abnormal fluctuation of stock trading specified in the trading rules of Shanghai Stock Exchange.
2、 Relevant information concerned and verified by the company
After the company’s self-examination and sent a letter to the actual controller, controlling shareholder and persons acting in concert of the company, the relevant information is verified as follows:
1. Production and operation.
According to the company’s self-examination, the company’s current business condition is normal, the internal and external business environment has not changed significantly, and there is no major information that should be disclosed but not disclosed.
2. Major events.
According to the company’s self-examination and verification by letter to the actual controllers, controlling shareholders and persons acting in concert, as of the disclosure date of this announcement, except for the information publicly disclosed on the designated media, there are no major matters that should be disclosed but not disclosed involving the listed company, including but not limited to major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset divestiture Asset injection, share repurchase, equity incentive, bankruptcy reorganization, major business cooperation, introduction of strategic investors and other major issues.
3. Media reports, market rumors and hot concepts.
Through the company’s self-examination, no media reports or market rumors that may have a significant impact on the company’s stock trading price are found, and the concept of market hot spots is not involved.
4. Other stock price sensitive information.
Through the company’s self-examination, no other major events that may have a great impact on the company’s share price are found. The actual controllers, controlling shareholders and persons acting in concert of the company do not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Relevant risk tips
The information disclosure media designated by the company are China Securities News, Shanghai Securities News, securities times, securities daily and the website of Shanghai Stock Exchange (www.sse. Com. CN), For company information, please refer to the announcement published in the above newspapers and websites. Please pay attention to and pay attention to investment risks.
4、 Board statement
The board of directors confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules or any planning, negotiation, intention, agreement, etc. related to such matters; The board of directors has not been informed of the information that should be disclosed but has not been disclosed according to the stock listing rules and other relevant provisions and may have a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
It is hereby announced.
Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) board of directors January 12, 2022
